Genezen Partners with Humane Genomics to Manufacture Novel Oncolytic Virus Therapy for Pediatric Liver Cancer
Key Insights
Genezen (search) and Humane Genomics (search) announced a manufacturing partnership for HGI627, a novel oncolytic virus therapy targeting pediatric liver cancer (search) (hepatoblastoma (search)).
The collaboration involves technology transfer, process development, and cGMP manufacturing of the VSV-based therapy using Humane Genomics (search)' proprietary synthetic RNA virus platform.
HGI627 utilizes a two-factor selectivity mechanism to infect and replicate only in targeted cancer (search) cells while leaving healthy tissue unharmed.
Genezen (search), a leading viral vector Contract Development and Manufacturing Organization (CDMO), has partnered with biotechnology company Humane Genomics (search) to advance manufacturing of HGI627, a novel oncolytic virus therapy targeting pediatric liver cancer (search) (hepatoblastoma (search)). The collaboration, announced November 12, 2025, focuses on process transfer and cGMP manufacturing of this innovative VSV-based therapy.
Novel RNA Virus Platform Technology
Humane Genomics (search) has developed a proprietary synthetic RNA virus platform that enables rapid design and engineering of RNA viruses with precise anti-cancer (search) capabilities. The platform's key innovation lies in its two-factor selectivity mechanism, which allows the therapeutic viruses to infect and replicate exclusively in targeted cancer cells while leaving healthy tissue unharmed.
This selective targeting approach represents a significant advancement in oncolytic virus therapy, potentially reducing the side effects commonly associated with traditional cancer (search) treatments. The company's platform powers a growing pipeline of next-generation viral therapies across multiple cancer types, with HGI627 serving as their lead candidate.
Manufacturing Partnership Details
Under the collaboration agreement, Genezen (search) will handle technology transfer, process development, and cGMP manufacturing of the VSV-based HGI627 therapy. This partnership leverages Genezen's extensive experience as a viral vector CDMO with over a decade of expertise and state-of-the-art manufacturing facilities.
"Genezen (search) is excited to partner with Humane Genomics (search) on this novel cancer (search) treatment and provide our best-in-class manufacturing expertise to bring this critical therapy to life for pediatric patients," said Steve Favaloro, chairman and chief executive officer of Genezen. "This partnership reinforces our commitment to supporting innovators at every stage of development and highlights the deep technical expertise and commitment to patients of the Genezen team."
Addressing Pediatric Cancer Needs
The focus on hepatoblastoma (search) represents a critical area of unmet medical need in pediatric oncology. Peter Weijmarshausen, co-founder and chief executive officer of Humane Genomics (search), emphasized the significance of this collaboration: "We are thrilled to partner with Genezen (search). Their experienced, dynamic team and state-of-the-art facilities make them a perfect match to turn our groundbreaking science into real therapies for patients."
Strategic Implications
This partnership positions both companies to advance innovative cancer (search) therapeutics through the combination of Humane Genomics (search)' cutting-edge RNA virus platform technology and Genezen (search)'s proven manufacturing capabilities. The collaboration spans from concept to commercial scale, reflecting Genezen's comprehensive approach to supporting gene and cell therapy innovators worldwide.
The VSV-based HGI627 therapy represents part of Humane Genomics (search)' broader pipeline of oncolytic viral therapies designed to selectively target cancer (search) cells across multiple cancer types, potentially expanding treatment options for patients with various malignancies.